ArticleCancer medicine2025
External Radiotherapy in Mozambique: Report of the First Five Years of Activity of the Radiotherapy Service of the Maputo Central Hospital.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundA Radiotherapy Service (RS) started working in the Maputo Central Hospital (MCH), Mozambique, in August 2019. Here we describe its first 5 years of activity.
methodsA total of 810 patients who underwent external radiotherapy between August 2019 and December 2023 were considered for the analysis. Sociodemographic and clinical data were retrieved from the RS database, and the MCH Cancer Registry was used to obtain cancer incidence data.
resultsThere was an increase in newly admitted patients each year, except in 2023 (161 in 2020, 188 in 2021, 238 in 2022, and 185 in 2023). Patients admitted in 2019 were more likely to be from Maputo city and to receive palliative radiotherapy. The proportion of patients starting radiotherapy within 12, 24, 36, and 48 months after diagnosis was 38.8%, 78.1%, 91.7%, and 96.6%, respectively. There was an increasing trend (p for trend < 0.001) in the proportion of patients admitted with cervical cancer over time (from 34.2% in 2019 to 46.0% in 2023). Differences in radiotherapy initiation within 12 months were observed according to treatment intent (42.6% for palliative vs. 36.9% for curative; p = 0.014) and cancer site (64.5% for rectal/anal cancer vs. 34.8%, 29.5%, and 37.0% for cervical, breast and prostate cancer patients, respectively; p < 0.001).
conclusionsThe RS-MCH improved access to radiotherapy for cancer patients, particularly those with cervical and breast cancers. Patients undergoing palliative treatment and those with anal/rectal cancers started radiotherapy earlier. Further research is needed to evaluate the impact of radiotherapy on mortality, survival, and in patient-centered outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.